SLCO1B3 Gene Mutation Analysis
The solute carrier organic anion transporter 1B3 (SLCO1B3) is an organic anion transporting polypeptide (OATP), coded by the gene SLCO1B3. It is located on loci 12 of the short arm (p) of the chromosome 12 and functions to promote uptake of various compounds from the blood by hepatocytes. SLCO1B3 polypeptide transports endogenous compounds such as bile salts, monoglucuronosyl bilirubin, bromosulfophthalein, steroid conjugates, the thyroid hormones T3 and T4, leukotriene C4, cyclic peptides; and clinically important drugs such as HMG-CoA- reductase inhibitors, cardiac glycosides, anticancer agents, and antibiotics. SLCO1B3 is involved in detoxification and hepatic clearance of xenobiotics including statins, taxanes, and mycophenolic acid. Mutations in SLCO1B3 impairs the normal clearance of these molecules by hepatocytes. Individuals who are compound heterozygotes for inactivating mutations in both SLCO1B3 and SLCO1B1 have Rotor syndrome.
Rotor syndrome is characterized by mild conjugated and unconjugated hyperbilirubinemia but individuals with this syndrome are otherwise clinically normal. These patients may present with icterus at birth and demonstrate mild jaundice as children and adults. Total bilirubin levels are typically 2-5 mg/dL but may be higher, than >50% of the bilirubin is conjugated. There is no evidence of hemolysis and ALT, AST, Alkaline Phosphatase and Gamma-glutamyl transpeptidase levels are normal. The urine my contain bilirubin, and elevated coproporphyrin levels.
Several drugs are taken up by hepatocytes via the OATP system and absence of SCLO1B1 and SLCO1B3 may impair the metabolism of these agents. Of these drugs the statins (simvastatin, atorvastatin, pravastatin, pitavastatin, rosuvastatin) are the most commonly prescribed. Impaired statin metabolism in these individuals may result in myositis or rhabdomyolysis Therapy with these drugs may need to be adjusted or avoided in patients with Rotor syndrome.
- Diagnosis of familial hyperbilirubinemia, especially Rotor syndrome
- Evaluation of suspected statin-induced myopathy and related diseases
334T>G TG or low SLCO1B3 transporter function
- Severely decreased SLCO1B3 transport function. The patient’s risk for statin induced myopathy is high
699G>A GA or low SLCO1B3 transporter function
- Severely decreased SLCO1B3 transport function. The patient’s risk for statin induced myopathy is high
334T>G TT or Normal SLCO1B3 transport function
699G>A GG or Normal SLCO1B3 transport function
334T>G TT or Normal SLCO1B3 transport function
699G>A GG or Normal SLCO1B3 transport function
Whole blood, lavender top tube (EDTA) or any anticoagulant collection devices, buccal swab.
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Pharmacogenetics. 2004 Jul;14(7):441-52. [PMID: 15226676]
- Biochim Biophys Acta. 2016 Nov;1858(11):2894-2902. [PMID: 27594653]
- Drug Metab Dispos. 2011 Jun;39(6):1047-53. [PMID: 21389119]
- Pharmacotherapy. 2006 Apr;26(4):469-78. [PMID: 16553504]
- Drug Metab Dispos. 2014 Sep;42(9):1514-21. [PMID: 24989890]